cas 196929-78-9|| where to buy (R)-2-methylpropane-2-sulfinamide

Nom du produit:(R)-2-methylpropane-2-sulfinamide

IUPAC Name:(R)-2-methylpropane-2-sulfinamide

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM112195-200g	in stock	Ǒƃ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 196929-78-9 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:196929-78-9; Formule moléculaire:C4H11NOS; Point de fusion:-; Code SMILES:CC([S@](N)=O)(C)C; Densité:

: Numéro de catalogue:CM112195; Poids moléculaire:121.2; Point d'ébullition:; N° Mdl:MFCD05861479; Stockage:Keep in a tight container and store at 2°C~8°C

: Nitrogen Compounds; Nitrogen compounds can be classified as mineral or organic. Mineral compounds are essentially formed by the ammonium ion (NH4+), which is generated when ammonium salts are dissolved in water. Organic compounds, in contrast, are carbon and hydrogen compounds that contain a nitrogen atom. All organic nitrogen-containing compounds can be considered as derivatives of ammonia in which one or more hydrogen atoms are substituted by hydrocarbon radicals.

: Repotrectinib; Repotrectinib receives approval for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) from the U.S. FDA on November 15, 2023. ROS1 gene is altered in about 1-2% of patients with NSCLC. ROS1-positive lung cancer tends to be aggressive and can spread to the brain and the bones.
Repotrectinib is a highly potent and differentiated small molecule TKI that binds inside the ATP pocket, and is active against both wild-type and resistant mutations, including solvent front and gatekeeper mutations. Repotrectinib is expected to enter the U.S. market in mid-December 2023.

: Olutasidenib; Rigel announces publication of data on REZLIDHIA(Olutasidenib) in post-venetoclax patients with mutant IDH1 AML in Leukemia & Lymphoma.
REZLIDHIA (Olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1), in patients with mIDH1 acute myeloid leukemia (AML) who were relapsed/refractory (R/R) to prior venetoclax-based regimens.